Kathy Lee-Sepsick

CIK: 0001857109

Transaction Breakdown

Open Market Buys (P)1 (6.7%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)8 (53.3%)

Compensation grants

Other (G, F, J, C, D, …)6 (40.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

FEMY

FEMASYS INC

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (15 total)

FEMY
FEMASYS INC
Aug 7, 2026
Award(A)
Common Stock Purchase Warrant
Direct
15.6K shares-
FEMY
FEMASYS INC
Aug 7, 2026
Award(A)
Common Stock Purchase Warrant (Milestone)
Direct
15.6K shares-
FEMY
FEMASYS INC
Aug 7, 2026
Purchase(P)
Direct
15.6K shares at avg. $3.20$50K
FEMY
FEMASYS INC
Mar 19, 2026
Award(A)
Series D-1 Warrants
Direct
68.2K shares-
FEMY
FEMASYS INC
Feb 19, 2026
Award(A)
Restricted Stock Units
Direct
447K shares-
FEMY
FEMASYS INC
Feb 19, 2026
Award(A)
Restricted Stock Units
Direct
282K shares-
FEMY
FEMASYS INC
Nov 7, 2025
Discretionary(I)
Series C-1 Warrants
Direct
68.2K shares-
FEMY
FEMASYS INC
Nov 7, 2025
Discretionary(I)
Senior Secured Convertible Notes
Direct
0 shares-
FEMY
FEMASYS INC
Nov 7, 2025
Discretionary(I)
Series A-1 Warrants
Direct
68.2K shares-
FEMY
FEMASYS INC
Nov 7, 2025
Discretionary(I)
Series B-1 Warrants
Direct
68.2K shares-
FEMY
FEMASYS INC
Aug 27, 2025
Discretionary(I)
Direct
48.5K shares-
FEMY
FEMASYS INC
Jun 2, 2025
Discretionary(I)
Direct
34.3K shares at avg. $1.02$35K
FEMY
FEMASYS INC
Jan 29, 2025
Award(A)
Stock Option (Right to Buy)
Direct
262.7K shares-
FEMY
FEMASYS INC
Jan 29, 2025
Award(A)
Stock Option (Right to Buy)
Direct
59.8K shares-
FEMY
FEMASYS INC
Jan 29, 2025
Award(A)
Stock Option (Right to Buy)
Direct
120.4K shares-

		Type	Shares	Price		Ownership
Aug 7, 2026	FEMY FEMASYS INC	Award(A) Common Stock Purchase Warrant	15,625	-	-	Direct
Aug 7, 2026	FEMY FEMASYS INC	Award(A) Common Stock Purchase Warrant (Milestone)	15,625	-	-	Direct
Aug 7, 2026	FEMY FEMASYS INC	Purchase(P)	15,625	$3.20	$50,000	Direct
Mar 19, 2026	FEMY FEMASYS INC	Award(A) Series D-1 Warrants	68,244	-	-	Direct
Feb 19, 2026	FEMY FEMASYS INC	Award(A) Restricted Stock Units	447,000	-	-	Direct
Feb 19, 2026	FEMY FEMASYS INC	Award(A) Restricted Stock Units	282,000	-	-	Direct
Nov 7, 2025	FEMY FEMASYS INC	Discretionary(I) Series C-1 Warrants	68,244	-	-	Direct
Nov 7, 2025	FEMY FEMASYS INC	Discretionary(I) Senior Secured Convertible Notes	0	-	-	Direct
Nov 7, 2025	FEMY FEMASYS INC	Discretionary(I) Series A-1 Warrants	68,244	-	-	Direct
Nov 7, 2025	FEMY FEMASYS INC	Discretionary(I) Series B-1 Warrants	68,244	-	-	Direct
Aug 27, 2025	FEMY FEMASYS INC	Discretionary(I)	48,535	-	-	Direct
Jun 2, 2025	FEMY FEMASYS INC	Discretionary(I)	34,314	$1.02	$35,000	Direct
Jan 29, 2025	FEMY FEMASYS INC	Award(A) Stock Option (Right to Buy)	262,700	-	-	Direct
Jan 29, 2025	FEMY FEMASYS INC	Award(A) Stock Option (Right to Buy)	59,849	-	-	Direct
Jan 29, 2025	FEMY FEMASYS INC	Award(A) Stock Option (Right to Buy)	120,353	-	-	Direct

1-15 of 15 transactions

About Lee-Sepsick Kathy

Lee-Sepsick Kathy (SEC CIK 0001857109) files insider reports with the SEC as Chief Executive Officer of FEMASYS INC (FEMY).

Signal8 holds 7 ownership filings by Lee-Sepsick Kathy, all Form 4s, filed between Jan 30, 2025 and Aug 11, 2026. Those filings report 15 transactions, from Jan 29, 2025 to Aug 7, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Lee-Sepsick Kathy's filings is in SUWANEE, GA.

Recent filings by Lee-Sepsick Kathy

Aug 7, 2026: Grants or awards of FEMY derivative securities (2 lines, Form 4, code A).
Aug 7, 2026: Open-market purchase of FEMY shares (Form 4, code P).
Mar 19, 2026: Grant or award of FEMY derivative securities (Form 4, code A).
Feb 19, 2026: Grants or awards of FEMY derivative securities (2 lines, Form 4, code A).
Nov 7, 2025: Discretionary transaction transactions of FEMY derivative securities (4 lines, Form 4, code I).

Other insiders filing for FEMASYS INC (FEMY)

Eichenbaum Kenneth D., Director
Uzialko Edward R, Director
Milnes Alistair, Director
Larsen Charles, Director
Mifek Jeffrey Gerald, Chief Clinical-Medical Affairs
Sipos Jeremy Alexander, Chief Technology Officer

How to read Form 4 transaction codes